Encouraged by the above finding, we further investigated the correlation between CDKN3 expression and patient survival in subgroups of neuroblastoma patients by stratifying the patients based on four clinical parameters, including age, gender, MYCN amplification status and tumor stages. This evidence concerns the gene MYCN and neuroblastoma.